Fidelity Management & Research Co has recently announced that it has increased stake in AlloVir Inc (NASDAQ:ALVR) by 1.69%. After grabbing 9.68 million shares, the institutional investor is now in possession of 0.16 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.49% having worth around $18.2 million. Moreover, GMT Capital Corp. increased its share by 0.11 million to have a control over 4.21 million shares. And BlackRock Fund Advisors raised its holdings to 0.45 million shares by acquiring 3.43 million shares or 3.00% of the stake.
AlloVir Inc (ALVR) concluded trading on 01/04/24 at a closing price of $0.67, with 3.06 million shares of worth about $2.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.13% during that period and on Thursday the price saw a gain of about 5.02%. Currently the company’s common shares owned by public are about 93.09M shares, out of which, 56.89M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 46 times over the past 12 months. They bought 4,005,370 shares in 14 of the transactions. In 32 selling transactions, insiders dumped 122,469 shares.
Fidelity Growth Company Fund, Wasatch Small Cap Growth Fund, and ACAP Strategic Fund are the top 3 mutual funds which are holding stakes in AlloVir Inc Fidelity Growth Company Fund is currently holding 2.69 million shares of worth totaling $5.05 million. The company recently came buying 0.0 shares which brought its stake up to 2.36% of the company’s outstanding shares. Wasatch Small Cap Growth Fund sold 79808.0 shares, after which its hold over company’s outstanding shares shrunk to 2.08%, leaving 2.38 million shares with the mutual fund that have a worth of about $4.47 million. ACAP Strategic Fund, after buying 2.3 million shares, have now control over 2.01% of the stake in the company. It holds 0.0 shares of worth $4.32 million.
However, the stock later moved at a day high price of 0.6876, or with a gain of 5.02%. Stock saw a price change of -3.95% in past 5 days and over the past one month there was a price change of -68.02%. Year-to-date (YTD), ALVR shares are showing a performance of -1.22% which decreased to -87.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.63 but also hit the highest price of $7.24 during that period. The average intraday trading volume for AlloVir Inc shares is 1.57 million. The stock is currently trading -60.88% below its 20-day simple moving average (SMA20), while that difference is down -59.07% for SMA50 and it goes to -77.41% lower than SMA200.
Fidelity Management & Research Co acquired 9.68 million shares of AlloVir Inc having value of about $18.2 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 0.16 million shares in the company valued at close to $107815.06, or have control over 1.69% stake in the company. AlloVir Inc (NASDAQ: ALVR) currently have 93.09M outstanding shares and institutions hold larger chunk of about 49.12% of that. Holding of mutual funds in the company is about 28.87% while other institutional holders and individual stake holders have control over 50.46% and 20.32% of the stake respectively.
The stock has a current market capitalization of $76.59M and its 3Y-monthly beta is at 0.82. It has posted earnings per share of -$1.72 in the same period. It has Quick Ratio of 6.65 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALVR, volatility over the week remained 7.89% while standing at 8.60% over the month.
Analysts are in expectations that AlloVir Inc (ALVR) stock would likely to be making an EPS of -$0.43 in the current quarter, while forecast for next quarter EPS is -$0.18 and it is -$0.49 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.53 which is -$0.33 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.37 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.67% while it is estimated to increase by 71.67% in next year.
Analysts at 5 brokerage firms have issued recommendations for the AlloVir Inc (ALVR)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.60. Out of those 5 Wall Street analysts, 0 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 26, 2023 offering an Underperform rating for the stock and assigned a target price range of between $17 and $1 to it.
